DK1206472T3 - Oxazol- og thiazolderivater som neutrophinproduktions/sekretionsfremmende middel - Google Patents

Oxazol- og thiazolderivater som neutrophinproduktions/sekretionsfremmende middel

Info

Publication number: DK1206472T3
Authority: DK; Denmark
Prior art keywords: neutrophin; oxazole; production; thiazole derivatives; secretion enhancer
Prior art date: 1999-08-25

Application number

DK00954966T

Other languages

English (en)

Inventor

Yu Momose

Katsuhito Murase

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-25

Filing date

2000-08-24

Publication date

2004-01-12

2000-08-24 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

2004-01-12 Application granted granted Critical

2004-01-12 Publication of DK1206472T3 publication Critical patent/DK1206472T3/da

Links

ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
239000003623 enhancer Substances 0.000 title 1
230000028327 secretion Effects 0.000 title 1
150000007979 thiazole derivatives Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/46—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Psychology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

DK00954966T 1999-08-25 2000-08-24 Oxazol- og thiazolderivater som neutrophinproduktions/sekretionsfremmende middel DK1206472T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP23891799		1999-08-25
PCT/JP2000/005681 WO2001014372A2 (en)	1999-08-25	2000-08-24	Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent

Publications (1)

Publication Number	Publication Date
DK1206472T3 true DK1206472T3 (da)	2004-01-12

Family

ID=17037204

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00954966T DK1206472T3 (da)	1999-08-25	2000-08-24	Oxazol- og thiazolderivater som neutrophinproduktions/sekretionsfremmende middel

Country Status (29)

Country	Link
US (3)	US6605629B1 (da)
EP (1)	EP1206472B1 (da)
JP (2)	JP3558588B2 (da)
KR (3)	KR100667646B1 (da)
CN (1)	CN1291985C (da)
AR (1)	AR035016A1 (da)
AT (1)	ATE251156T1 (da)
AU (1)	AU780307B2 (da)
BR (1)	BR0013493B1 (da)
CA (1)	CA2382355C (da)
CZ (1)	CZ303101B6 (da)
DE (1)	DE60005695T2 (da)
DK (1)	DK1206472T3 (da)
ES (1)	ES2206292T3 (da)
HK (1)	HK1044762B (da)
HU (1)	HU228507B1 (da)
IL (2)	IL148020A0 (da)
MX (1)	MXPA01013453A (da)
MY (1)	MY128113A (da)
NO (1)	NO322499B1 (da)
PE (1)	PE20010527A1 (da)
PL (1)	PL205532B1 (da)
PT (1)	PT1206472E (da)
RU (1)	RU2260003C2 (da)
SI (1)	SI1206472T1 (da)
SK (1)	SK285938B6 (da)
TW (1)	TWI268929B (da)
WO (1)	WO2001014372A2 (da)
ZA (1)	ZA200201044B (da)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR035016A1 (es) *	1999-08-25	2004-04-14	Takeda Chemical Industries Ltd	Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
JP4590159B2 (ja)	2001-04-04	2010-12-01	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
CA2443325C (en)	2001-04-04	2011-06-14	Ortho-Mcneil Pharmaceutical, Inc.	Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
EP1407770B1 (en)	2001-06-26	2013-06-05	Takeda Pharmaceutical Company Limited	Tgf-beta superfamily production/secretion promoter
AU2002367426A1 (en) *	2001-12-28	2003-07-24	Takeda Chemical Industries, Ltd.	Neurotrophic factor production/secretion accelerator
GB0203412D0 (en)	2002-02-13	2002-04-03	Pharmagene Lab Ltd	5-HT 2B receptor antagonists
EP1486490A1 (en)	2002-02-28	2004-12-15	Takeda Chemical Industries, Ltd.	Azole compounds
JP4484439B2 (ja) *	2002-03-14	2010-06-16	国立大学法人東京工業大学	Ｖｄａｃ調節剤
EP1491194B1 (en) *	2002-03-14	2013-10-30	Takeda Pharmaceutical Company Limited	Vdac regulator
EP1556032A1 (en)	2002-11-01	2005-07-27	Takeda Pharmaceutical Company Limited	Agent for preventing or treating neuropathy
EP1559422B1 (en)	2002-11-08	2014-04-30	Takeda Pharmaceutical Company Limited	Receptor function controlling agent
US7202257B2 (en)	2003-12-24	2007-04-10	Deciphera Pharmaceuticals, Llc	Anti-inflammatory medicaments
US7144911B2 (en)	2002-12-31	2006-12-05	Deciphera Pharmaceuticals Llc	Anti-inflammatory medicaments
US7279576B2 (en)	2002-12-31	2007-10-09	Deciphera Pharmaceuticals, Llc	Anti-cancer medicaments
RU2361582C2 (ru) *	2003-06-25	2009-07-20	Новартис Аг	Таблетка, содержащая флувастатин и кармеллозу кальция
CN100398536C (zh) *	2003-08-20	2008-07-02	爱密斯菲尔科技公司	用于口服传递glp-1化合物或mc4激动剂肽的化合物、方法和制剂
JP4767850B2 (ja)	2003-08-20	2011-09-07	エミスフィアーテクノロジーズインコーポレイテッド	グルカゴン様ペプチド（ｇｌｐ）−１化合物またはメラノコルチン４受容体（ｍｃ４）アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
GEP20084570B (en)	2003-10-31	2008-12-25	Takeda Pharmaceutical	Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
JP4638355B2 (ja) *	2003-12-26	2011-02-23	協和発酵キリン株式会社	チアゾール誘導体
JP2007519720A (ja) *	2004-01-28	2007-07-19	スミスクラインビーチャムコーポレーション	チアゾール化合物
US20050282840A1 (en) *	2004-02-11	2005-12-22	Painceptor Pharma Corporation	Methods of modulating neurotrophin-mediated activity
EP2253315A1 (en)	2004-03-30	2010-11-24	Takeda Pharmaceutical Company Limited	Alkoxyphenylpropanoic acid derivatives
WO2005097113A2 (en) *	2004-04-08	2005-10-20	Pharmagene Laboratories Limited	5-ht2b receptor antagonists
JP5094394B2 (ja)	2005-04-20	2012-12-12	武田薬品工業株式会社	縮合複素環化合物
WO2006118320A1 (ja)	2005-04-28	2006-11-09	Takeda Pharmaceutical Company Limited	チエノピリミドン化合物
WO2006132440A1 (ja)	2005-06-09	2006-12-14	Takeda Pharmaceutical Company Limited	固形製剤
MY152185A (en)	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US20100280023A1 (en) *	2005-06-23	2010-11-04	Kyowa Hakko Kogyo Co., Ltd.	Thiazole derivatives
PL1931350T5 (pl)	2005-09-14	2021-11-15	Takeda Pharmaceutical Company Limited	Podanie inhibitorów dipeptydylo-peptydazy
JP5094416B2 (ja)	2005-12-28	2012-12-12	武田薬品工業株式会社	糖尿病治療剤
JPWO2007119833A1 (ja)	2006-04-14	2009-08-27	武田薬品工業株式会社	含窒素複素環化合物
CL2007001873A1 (es)	2006-06-27	2008-01-04	Takeda Pharmaceutical	Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
CN101096363B (zh) *	2006-06-27	2011-05-11	中国人民解放军军事医学科学院毒物药物研究所	2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
US20100029619A1 (en)	2006-08-04	2010-02-04	Takeda Pharmaceutical Company Limted	Fused heterocyclic compound
US8492405B2 (en)	2006-10-18	2013-07-23	Takeda Pharmaceutical Company Limited	Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
UA97257C2 (en)	2006-10-19	2012-01-25	Такеда Фармасьютикал Компани Лимитед	Indole derivatives
EP2256115A1 (en)	2006-11-24	2010-12-01	Takeda Pharmaceutical Company Limited	Heteromonocyclic compound and use thereof
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2128163A1 (en)	2007-01-25	2009-12-02	Takeda Pharmaceutical Company Limited	Spiro-ring compound
JPWO2008093639A1 (ja)	2007-01-29	2010-05-20	武田薬品工業株式会社	ピラゾール化合物
JPWO2008102749A1 (ja)	2007-02-20	2010-05-27	武田薬品工業株式会社	複素環化合物
WO2008136428A1 (ja)	2007-04-27	2008-11-13	Takeda Pharmaceutical Company Limited	含窒素５員複素環化合物
WO2009015917A2 (en) *	2007-05-14	2009-02-05	F. Hoffmann-La Roche Ag	Dihydroquinone and dihydronaphthridine inhibitors of jnk
WO2008143262A1 (ja)	2007-05-21	2008-11-27	Takeda Pharmaceutical Company Limited	複素環化合物およびその用途
TW200914006A (en)	2007-07-12	2009-04-01	Takeda Pharmaceutical	Coated preparation
JP5489997B2 (ja)	2007-07-19	2014-05-14	シマベイセラピューティクス，インコーポレーテッド	糖尿病および代謝疾患の治療のためのＲＵＰ３またはＧＰＲｌ１９受容体のアゴニストとしてのＮ−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体
UA98799C2 (ru)	2007-07-19	2012-06-25	Такеда Фармасьютикал Компани Лимитед	Твердый препарат, включающий алоглиптин и гидрохлорид метформина
EP2457567B1 (en)	2007-09-19	2015-12-30	Nagoya Industrial Science Research Institute	Agent having neurotrophic factor-like activity
EP2202223B1 (en)	2007-10-18	2017-01-25	Takeda Pharmaceutical Company Limited	Heterocyclic compound as blood rbp4 lowering agent
EP2210876B1 (en)	2007-11-01	2015-05-20	Takeda Pharmaceutical Company Limited	Heterocyclic compound as glucagon antagonist
MY157189A (en)	2008-01-10	2016-05-13	Takeda Pharmaceutical	Capsule formulation
BRPI0912245A2 (pt)	2008-03-05	2019-09-24	Takeda Pharmaceuticals Co	composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
WO2009123194A1 (ja)	2008-04-01	2009-10-08	武田薬品工業株式会社	複素環化合物
WO2009123316A1 (ja)	2008-04-04	2009-10-08	武田薬品工業株式会社	複素環誘導体及びその用途
WO2009128481A1 (ja)	2008-04-16	2009-10-22	武田薬品工業株式会社	含窒素５員複素環化合物
BRPI0913291A2 (pt)	2008-05-30	2019-01-15	Takeda Pharmaceuticals Co	composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
WO2010016552A1 (ja)	2008-08-07	2010-02-11	武田薬品工業株式会社	過敏性腸症候群治療薬
AR073380A1 (es)	2008-09-25	2010-11-03	Takeda Pharmaceutical	Composicion farmaceutica solida. comprimido multicapa
JP5535931B2 (ja)	2008-10-27	2014-07-02	武田薬品工業株式会社	二環性化合物
WO2010076884A1 (ja)	2008-12-29	2010-07-08	武田薬品工業株式会社	新規縮合環化合物およびその用途
US20100190747A1 (en)	2009-01-27	2010-07-29	Hideo Suzuki	Fused ring compound and use thereof
EP2419413B1 (en)	2009-04-16	2016-11-23	Takeda Pharmaceutical Company Limited	Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
JP2010254623A (ja)	2009-04-24	2010-11-11	Takeda Chem Ind Ltd	ベンゾオキサジノン化合物の結晶
US20100307042A1 (en)	2009-06-05	2010-12-09	Michael Brent Jarboe	Modular firearm stock system
WO2010143733A1 (en)	2009-06-09	2010-12-16	Takeda Pharmaceutical Company Limited	Novel fused cyclic compound and use thereof
BR112012001959A2 (pt)	2009-07-28	2016-03-15	Takeda Pharmaceutical	comprimido,e, método para reproduzir um comprimido
WO2011041293A1 (en)	2009-09-30	2011-04-07	Takeda Pharmaceutical Company Limited	Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
WO2011041154A1 (en)	2009-10-01	2011-04-07	Metabolex, Inc.	Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011097079A1 (en)	2010-02-03	2011-08-11	Takeda Pharmaceutical Company Limited	Apoptosis signal-regulating kinase 1 inhibitors
CN103025716B (zh)	2010-04-27	2014-12-24	武田药品工业株式会社	二环化合物衍生物及其作为acc抑制剂的用途
ES2524896T3 (es)	2010-06-16	2014-12-15	Takeda Pharmaceutical Company Limited	Cristal de compuesto de amida
CA2806258A1 (en)	2010-07-23	2012-01-26	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound and application thereof
JP2012050904A (ja) *	2010-08-31	2012-03-15	Panasonic Electric Works Co Ltd	浄水カートリッジ、当該浄水カートリッジを備えた浄水装置および当該浄水装置を備えた流し台
EP2617726A4 (en)	2010-09-17	2014-05-14	Takeda Pharmaceutical	DIABETES THERAPEUTIC
JP2013209295A (ja)	2010-10-13	2013-10-10	Takeda Chem Ind Ltd	ペプチド誘導体
BR112013010709A2 (pt)	2010-11-02	2019-09-24	Nagoya Industrial Science Res Institute	derivado de ácido trans-2-decenoico e agente farmacêutico contendo o mesmo
US8729102B2 (en)	2010-11-30	2014-05-20	Takeda Pharmaceutical Company Limited	Bicyclic compound
JP2012158527A (ja) *	2011-01-31	2012-08-23	Mitsubishi Gas Chemical Co Inc	うつ予防
WO2012111849A1 (en)	2011-02-17	2012-08-23	Takeda Pharmaceutical Company Limited	Production method of optically active dihydrobenzofuran derivative
TW201311679A (zh)	2011-08-04	2013-03-16	Takeda Pharmaceutical	含氮雜環化合物
CA2851087C (en)	2011-10-07	2019-09-24	Takeda Pharmaceutical Company Limited	1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
CA2853221A1 (en)	2011-10-24	2013-05-02	Tohru Yamashita	Bicyclic compound
WO2013105676A1 (en)	2012-01-12	2013-07-18	Takeda Pharmaceutical Company Limited	Benzimidazole derivatives as mch receptor antagonists
US9382188B2 (en)	2012-02-13	2016-07-05	Takeda Pharmaceutical Company Limited	Aromatic ring compound
EP2816032A4 (en)	2012-02-13	2015-09-30	Takeda Pharmaceutical	AROMATIC RING CONNECTION
WO2013122260A1 (en)	2012-02-15	2013-08-22	Takeda Pharmaceutical Company Limited	Tablet
US9238639B2 (en)	2012-02-24	2016-01-19	Takeda Pharmaceutical Company Limited	Aromatic ring compound
US9073864B2 (en)	2012-03-29	2015-07-07	Takeda Pharmaceutical Company Limted	Aromatic ring compound
US9440987B2 (en)	2012-05-10	2016-09-13	Takeda Pharmaceutical Company Limited	Aromatic ring compound
EP2848622A4 (en)	2012-05-10	2015-11-04	Takeda Pharmaceutical	Aromatic ring compound
JP6122879B2 (ja)	2012-06-05	2017-04-26	武田薬品工業株式会社	固形製剤
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP6299591B2 (ja)	2012-07-03	2018-03-28	小野薬品工業株式会社	ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
JP2015127299A (ja)	2012-07-19	2015-07-09	武田薬品工業株式会社	固形製剤
US20150299188A1 (en)	2012-08-24	2015-10-22	Takeda Pharmaceutical Company Limited	Heterocyclic compound
US8844185B2 (en)	2012-08-27	2014-09-30	Ra Brands, L.L.C.	Buttstock assembly
USD704294S1 (en)	2012-09-19	2014-05-06	Ra Brands, L.L.C.	Buttstock
WO2014061676A1 (ja)	2012-10-16	2014-04-24	武田薬品工業株式会社	複素環化合物
JP6247697B2 (ja)	2013-03-14	2017-12-13	武田薬品工業株式会社	スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用
EP2982670B1 (en)	2013-04-04	2018-11-07	Takeda Pharmaceutical Company Limited	Heterocyclic compound
US9598398B2 (en)	2013-04-04	2017-03-21	Takeda Pharmaceutical Company Limited	Heterocyclic compound
AR096848A1 (es)	2013-07-09	2016-02-03	Takeda Pharmaceuticals Co	Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch)
JP6397410B2 (ja)	2013-08-09	2018-09-26	武田薬品工業株式会社	芳香環化合物
BR112016007078A2 (pt)	2013-09-30	2017-12-12	Ono Pharmaceutical Co	composto tendo atividade agonística do receptor de somatostatina e uso farmacêutico do mesmo
US9346776B2 (en)	2014-02-13	2016-05-24	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
JP6533799B2 (ja)	2014-06-09	2019-06-19	武田薬品工業株式会社	放射標識された化合物
CN107108506B (zh)	2014-10-24	2022-06-21	武田药品工业株式会社	杂环化合物
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
EP3493807A1 (en)	2016-08-03	2019-06-12	CymaBay Therapeutics, Inc.	Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
MX2019009419A (es)	2017-02-08	2019-10-02	Ono Pharmaceutical Co	Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo.
AR111307A1 (es)	2017-03-30	2019-06-26	Takeda Pharmaceuticals Co	Derivados de 1,2-dihidroespiro[ciclohexan-1,3-indol] o 1,2-dihidroespiro[ciclohexan-1,3-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa
AR111199A1 (es)	2017-03-31	2019-06-12	Takeda Pharmaceuticals Co	Compuesto aromático agonista de gpr40
WO2018181847A1 (ja)	2017-03-31	2018-10-04	武田薬品工業株式会社	芳香環化合物
CN109020808B (zh) *	2017-06-12	2021-07-06	浙江九洲药业股份有限公司	一种取代苯乙酸衍生物的制备方法
EP3746059B1 (en)	2018-01-31	2026-03-04	Deciphera Pharmaceuticals, LLC	Combination therapy for the treatment of gastrointestinal stromal tumors
AU2019216351B2 (en)	2018-01-31	2024-07-25	Deciphera Pharmaceuticals, Llc	Combination therapy for the treatment of mastocytosis
WO2020045326A1 (ja)	2018-08-27	2020-03-05	株式会社スコヒアファーマ	安息香酸エステル化合物
WO2020067575A1 (en)	2018-09-24	2020-04-02	Takeda Pharmaceutical Company Limited	Gip receptor agonist peptide compounds and uses thereof
JP2022503793A (ja)	2018-09-24	2022-01-12	武田薬品工業株式会社	Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
WO2020185812A1 (en)	2019-03-11	2020-09-17	Teva Pharmaceuticals International Gmbh	Solid state forms of ripretinib
TWI855081B (zh)	2019-05-24	2024-09-11	美商賽吉醫療公司	化合物、組合物及使用方法
FI4013412T3 (fi)	2019-08-12	2026-03-24	Deciphera Pharmaceuticals Llc	Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
TWI878335B (zh)	2019-08-12	2025-04-01	美商迪賽孚爾製藥有限公司	治療胃腸道基質瘤方法
PL4084779T3 (pl)	2019-12-30	2025-02-24	Deciphera Pharmaceuticals, Llc	Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
AU2020419197B2 (en)	2019-12-30	2023-08-31	Deciphera Pharmaceuticals, Llc	Amorphous kinase inhibitor formulations and methods of use thereof
PE20231066A1 (es)	2020-02-07	2023-07-17	Gasherbrum Bio Inc	Agonistas heterociclicos de glp-1
JP2023519446A (ja)	2020-03-25	2023-05-10	武田薬品工業株式会社	Ｇｉｐ受容体アゴニストペプチド化合物のｑｄ投薬及びその使用
EP4143183B1 (en)	2020-04-29	2025-10-22	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
IL308392A (en)	2021-05-13	2024-01-01	Carmot Therapeutics Inc	G protein-coupled receptor modulators
CN114306291B (zh) *	2022-01-13	2023-06-27	云南大学	一种化合物在预防和/或治疗癌症中的用途
JP2025509281A (ja)	2022-03-09	2025-04-11	ガシャーブラム・バイオ・インコーポレイテッド	ヘテロ環式ｇｌｐ－１アゴニスト
EP4496797A1 (en)	2022-03-21	2025-01-29	Gasherbrum Bio, Inc.	5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4508047A1 (en)	2022-04-14	2025-02-19	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors
KR20250157491A (ko)	2022-12-15	2025-11-04	가셔브룸 바이오, 인크.	Glp-1 효능제 활성을 갖는 화합물의 염 및 고체 형태
EP4638440A1 (en)	2022-12-22	2025-10-29	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
CN120693338A (zh)	2022-12-22	2025-09-23	加舒布鲁姆生物公司	杂环的glp-1激动剂
IL322686A (en)	2023-02-16	2025-10-01	Gasherbrum Bio Inc	Heterocyclic glp-1 agonists
KR102829053B1 (ko)	2023-03-29	2025-07-04	원광대학교산학협력단	위생적 처리 구조를 지닌 소변백
CN121773120A (zh)	2023-06-30	2026-03-31	加舒布鲁姆生物公司	杂环glp-1激动剂
EP4743174A1 (en)	2023-07-13	2026-05-20	Aconcagua Bio Inc	CALCITONIN AND/OR AMYLIN RECEPTOR ACTIVITY MODULATORS
AR133241A1 (es)	2023-07-13	2025-09-10	Aconcagua Bio Inc	Compuestos, composiciones y métodos
WO2025045208A1 (en)	2023-08-31	2025-03-06	Gasherbrum Bio, Inc.	Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en)	2023-12-20	2025-06-26	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
WO2025154021A1 (en)	2024-01-19	2025-07-24	Takeda Pharmaceutical Company Limited	Improved gip receptor agonist peptide compounds and uses thereof
WO2025154020A1 (en)	2024-01-19	2025-07-24	Takeda Pharmaceutical Company Limited	Improved gip receptor agonist peptide compounds and uses thereof
WO2025171340A1 (en)	2024-02-08	2025-08-14	Aconcagua Bio, Inc.	The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025189141A1 (en)	2024-03-08	2025-09-12	Annapurna Bio, Inc.	Methods for treating obesity and increasing weight loss
WO2026041075A1 (en)	2024-08-21	2026-02-26	Gasherbrum Bio, Inc.	Gpl-1 agonists
WO2026051998A1 (en)	2024-09-04	2026-03-12	Aconcagua Bio, Inc.	Compounds, compositions, and methods
WO2026096926A1 (en)	2024-11-01	2026-05-07	Aconcagua Bio, Inc.	Compounds, compositions, and methods
CN120753343B (zh) *	2025-07-30	2026-03-06	中国科学院水生生物研究所	辣椒素在制备防治鱼类病毒感染的饲料添加剂和/或药物中的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3575991A (en)	1969-03-11	1971-04-20	American Home Prod	1-(4-aryl - 5 - carboxymethyl-2-thiazolyl)-1,6-dihydro -6 - oxonicotinic acids and esters thereof
JPS5188964A (ja) *	1975-01-30	1976-08-04		Chiazorirusakusanjudotaino seizoho
GB1574583A (en)	1978-02-09	1980-09-10	Wyeth John & Brother Ltd	Process for preparing thiazoles
AU6610081A (en)	1980-01-24	1981-07-30	Senju Pharmaceutical Co., Ltd.	Thiazolidine derivatives
JPH0725754B2 (ja)	1986-01-30	1995-03-22	富山化学工業株式会社	新規なチアゾール化合物またはその塩
JPS62234018A (ja)	1986-04-02	1987-10-14	Rooto Seiyaku Kk	糖尿病併発症治療剤
GB8610432D0 (en) *	1986-04-29	1986-06-04	Akzo Nv	Amino-thiazole & oxazole derivatives
FR2656610B1 (fr) *	1989-12-29	1992-05-07	Sanofi Sa	Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique.
EP0555149B1 (en)	1992-02-07	1997-08-27	Mitsubishi Gas Chemical Company, Inc.	Use of oxazopyrroloquinolines and pyrroloquinolinequinones for the manufacture of nerve growth factor production accelerators
SE9302332D0 (sv)	1993-07-06	1993-07-06	Ab Astra	New compounds
JP3362494B2 (ja) *	1994-03-01	2003-01-07	三菱ウェルファーマ株式会社	ベンゾオキサジン化合物
JPH08175992A (ja) *	1994-12-21	1996-07-09	Sagami Chem Res Center	神経成長因子産生促進剤および縮環型オキサゾール化合物
EP0891340B1 (en)	1996-04-03	2002-11-13	Takeda Chemical Industries, Ltd.	Oxazole derivatives, their production and use
JP4289688B2 (ja) *	1996-04-03	2009-07-01	武田薬品工業株式会社	オキサゾール誘導体、その製造法および剤
US5952360A (en)	1997-08-28	1999-09-14	Eli Lilly And Company	Method for treating neuropathic pain
JP2001518449A (ja) *	1997-09-30	2001-10-16	デューク・ユニバーシティー	アポリポタンパク質ｅ／成長因子複合体およびその使用法
CA2332178A1 (en)	1998-07-01	2000-01-13	Takeda Chemical Industries, Ltd.	Retinoid-associated receptor function regulating agent
AR035016A1 (es) *	1999-08-25	2004-04-14	Takeda Chemical Industries Ltd	Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CN1204128C (zh)	1999-09-16	2005-06-01	武田药品工业株式会社	制备噁唑衍生物的方法

2000
- 2000-08-23 AR ARP000104356A patent/AR035016A1/es active IP Right Grant
- 2000-08-24 KR KR1020057003905A patent/KR100667646B1/ko not_active Expired - Fee Related
- 2000-08-24 CA CA2382355A patent/CA2382355C/en not_active Expired - Fee Related
- 2000-08-24 SK SK247-2002A patent/SK285938B6/sk not_active IP Right Cessation
- 2000-08-24 CZ CZ20020446A patent/CZ303101B6/cs not_active IP Right Cessation
- 2000-08-24 DK DK00954966T patent/DK1206472T3/da active
- 2000-08-24 RU RU2002107321/04A patent/RU2260003C2/ru not_active IP Right Cessation
- 2000-08-24 US US09/868,304 patent/US6605629B1/en not_active Expired - Lifetime
- 2000-08-24 CN CNB008124531A patent/CN1291985C/zh not_active Expired - Fee Related
- 2000-08-24 PE PE2000000870A patent/PE20010527A1/es not_active Application Discontinuation
- 2000-08-24 PT PT00954966T patent/PT1206472E/pt unknown
- 2000-08-24 SI SI200030255T patent/SI1206472T1/xx unknown
- 2000-08-24 IL IL14802000A patent/IL148020A0/xx active IP Right Grant
- 2000-08-24 KR KR10-2004-7016910A patent/KR100486331B1/ko not_active Expired - Fee Related
- 2000-08-24 MY MYPI20003914A patent/MY128113A/en unknown
- 2000-08-24 HK HK02105926.6A patent/HK1044762B/en not_active IP Right Cessation
- 2000-08-24 ES ES00954966T patent/ES2206292T3/es not_active Expired - Lifetime
- 2000-08-24 PL PL354333A patent/PL205532B1/pl unknown
- 2000-08-24 MX MXPA01013453A patent/MXPA01013453A/es active IP Right Grant
- 2000-08-24 HU HU0302046A patent/HU228507B1/hu not_active IP Right Cessation
- 2000-08-24 DE DE60005695T patent/DE60005695T2/de not_active Expired - Lifetime
- 2000-08-24 EP EP00954966A patent/EP1206472B1/en not_active Expired - Lifetime
- 2000-08-24 KR KR1020017008674A patent/KR20020060066A/ko not_active Ceased
- 2000-08-24 WO PCT/JP2000/005681 patent/WO2001014372A2/en not_active Ceased
- 2000-08-24 TW TW089117045A patent/TWI268929B/zh not_active IP Right Cessation
- 2000-08-24 JP JP2000259390A patent/JP3558588B2/ja not_active Expired - Fee Related
- 2000-08-24 AT AT00954966T patent/ATE251156T1/de active
- 2000-08-24 AU AU67276/00A patent/AU780307B2/en not_active Ceased
- 2000-08-24 BR BRPI0013493-7B1A patent/BR0013493B1/pt not_active IP Right Cessation
2001
- 2001-07-05 JP JP2001205451A patent/JP2002080467A/ja active Pending
2002
- 2002-02-05 IL IL148020A patent/IL148020A/en not_active IP Right Cessation
- 2002-02-06 ZA ZA200201044A patent/ZA200201044B/xx unknown
- 2002-02-20 NO NO20020831A patent/NO322499B1/no not_active IP Right Cessation
2003
- 2003-07-10 US US10/616,769 patent/US7396848B1/en not_active Expired - Fee Related
2008
- 2008-04-03 US US12/080,461 patent/US8067453B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BR0013493B1 (pt)	2013-10-01
AU780307B2 (en)	2005-03-17
DE60005695D1 (de)	2003-11-06
US20080269219A1 (en)	2008-10-30
IL148020A0 (en)	2002-09-12
KR20020060066A (ko)	2002-07-16
CN1372557A (zh)	2002-10-02
PL354333A1 (en)	2004-01-12
US8067453B2 (en)	2011-11-29
HUP0302046A2 (hu)	2003-10-28
PT1206472E (pt)	2004-06-30
SK285938B6 (sk)	2007-11-02
JP3558588B2 (ja)	2004-08-25
EP1206472A1 (en)	2002-05-22
JP2001131161A (ja)	2001-05-15
RU2260003C2 (ru)	2005-09-10
PL205532B1 (pl)	2010-04-30
HK1044762B (en)	2004-01-21
ES2206292T3 (es)	2004-05-16
CN1291985C (zh)	2006-12-27
KR20050043933A (ko)	2005-05-11
TWI268929B (en)	2006-12-21
MXPA01013453A (es)	2002-11-22
NO20020831D0 (no)	2002-02-20
KR100667646B1 (ko)	2007-01-12
HU228507B1 (hu)	2013-03-28
KR100486331B1 (ko)	2005-04-29
BR0013493A (pt)	2002-05-14
ATE251156T1 (de)	2003-10-15
PE20010527A1 (es)	2001-05-18
NO322499B1 (no)	2006-10-16
MY128113A (en)	2007-01-31
JP2002080467A (ja)	2002-03-19
AU6727600A (en)	2001-03-19
US6605629B1 (en)	2003-08-12
AR035016A1 (es)	2004-04-14
EP1206472B1 (en)	2003-10-01
WO2001014372A2 (en)	2001-03-01
CA2382355A1 (en)	2001-03-01
ZA200201044B (en)	2003-04-30
CZ303101B6 (cs)	2012-04-04
CZ2002446A3 (cs)	2002-06-12
NO20020831L (no)	2002-04-24
HUP0302046A3 (en)	2007-03-28
WO2001014372A3 (en)	2002-03-21
SI1206472T1 (en)	2004-02-29
SK2472002A3 (en)	2002-07-02
IL148020A (en)	2007-02-11
US7396848B1 (en)	2008-07-08
CA2382355C (en)	2010-06-22
DE60005695T2 (de)	2004-08-19
KR20040101549A (ko)	2004-12-02
HK1044762A1 (en)	2002-11-01

Publication	Publication Date	Title
DK1244642T3 (da)	2004-08-16	Substituerede oxazol- og thiazolderivater som HPPAR-alfa-aktivatorer
ZA200201044B (en)	2003-04-30	Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent.
EP1189895B8 (en)	2005-11-09	Thiazole and oxazole derivatives and their pharmaceutical use
NO20025978L (no)	2002-12-12	Benzotiazol-derivater
LV12755B (lv)	2002-04-20	Pie c-21 modificetie epotiloni
PL372969A1 (en)	2005-08-08	Thiazole and oxazole derivatives which modulate ppar activity
NO20044245L (no)	2004-10-06	Tiazol- og oksazolderivater som modulerer PPAR-aktivitet
NO20010628D0 (no)	2001-02-06	Substituerte oksazol- og thiazolderivater som hPPAR <gamma> og hPPAR <alfa> aktivatorer
ATE391505T1 (de)	2008-04-15	Benzothiazole derivative
DK1244641T3 (da)	2005-07-11	Thiazolylamid-derivater
TR199802765A3 (tr)	1999-07-21	Tiyazol türevleri.
CY2009001I1 (el)	2009-11-04	Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης
AU2001292285A1 (en)	2002-04-15	Thiazole or oxazole derivatives
AUPQ309399A0 (en)	1999-10-21	Benzothiazoline derivatives
PL375416A1 (en)	2005-11-28	Thiazole derivatives
DK1200419T3 (da)	2004-07-19	Aminothiazolderivater og disses anvendelse som ligander for CRF-receptorer
AU2001248820A1 (en)	2001-11-12	Thiazole and oxazole derivatives
DK1231211T3 (da)	2003-10-27	Thiazolidindion-derivater som antidiabetika
NO20035209D0 (no)	2003-11-24	Oksazol/Tiazol-derivataktivatorer av HPPAR-alfa reseptoren
IS6093A (is)	2001-09-28	Notkun á madúraþalazín afleiðum sem lötum fyrir for-bólgu frumuboða
MXPA03001550A (es)	2003-06-06	Proceso catalitico para la preparacion de derivados de tiazol.
HUP0202819A3 (en)	2004-03-01	Process for the preparation of thiazole derivatives and the new intermediates
IL155224A0 (en)	2003-11-23	Process for the manufacture of thiazole derivatives with pesticidal activity
PL360544A1 (en)	2004-09-06	Thiazole derivatives of 2-methoxyimino-2-(pyridinyloxymethyl)-phenyl-acetamides useful as fungicides
AU6267100A (en)	2001-01-30	Vinylpyrrolidinone derivatives with substituted thiazole ring